Navigation Links
Amarantus BioSciences Wins MANF Patent Challenge in Europe
Date:11/20/2012

SUNNYVALE, Calif., Nov. 20, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced the Opposition Division of the European Patent Office upheld Amarantus Bioscience's European Patent relating to neurotrophic factor MANF, following opposition by rival Hermo Pharma OY of Finland. 

The Opposition Division held that the Opponent's arguments did not prejudice the maintenance of the Patent as originally granted, with broad claims covering MANF and its derivatives.  The Opponent had not contested the validity of the Patent on the basis of novelty or inventive step, but had objected to the broad scope of the claims. However, after due consideration of comprehensive legal and technical oral submissions from both sides, the Opposition Division rejected the Opponent's arguments and upheld the claims without restriction. 

"This is a highly significant decision for Amarantus, after an extended period of uncertainty," said Marc Wilkinson PhD, European Patent Attorney of UK firm Avidity IP, representing Amarantus.  "The Opposition Division's decision validates broad protection for MANF and derivatives across major European jurisdictions."

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for bra
'/>"/>

SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amarantus BioSciences Issues CEO Letter to Shareholders
2. Amarantus BioSciences Secures $1.1 Million in Financing
3. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
4. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
5. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
6. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
7. Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
8. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
9. IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of Regenerative Medicine in London
10. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
11. Neurocrine Biosciences Reports Third Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... Agritech Limited (NASDAQ GS: SEED) ("Origin", or the "Company"), a ... , today announced that the Company will report results for ... before the market opens on Wednesday, August 5th, 2015. ... 2015, at 9:00 a.m. ET / 9:00 p.m. ... in the call, please dial the following numbers approximately 5 ...
(Date:7/24/2015)... ... July 24, 2015 , ... ... to any modern scientific or pharmaceutical laboratory. FreezerPro® is an intuitive, fast, ... precisely where a sample is located even before opening the freezer door! ...
(Date:7/23/2015)... (PRWEB) , ... July 23, 2015 , ... Science and ... radiation, to new drug therapies and devices – according to Susan Chang, MD, director ... a session on how science and new technology are impacting the development of new ...
(Date:7/23/2015)... ... July 23, 2015 , ... July ... by providing more targeted treatment options with fewer side effects, according to Erik ... Anderson Cancer Center. , At the American Brain Tumor Association (ABTA) National Patient ...
Breaking Biology Technology:Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 3RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 2RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 3RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 4Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 2Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 3Radiation Oncology Advances Improve Safety and Efficacy of Treatment for Brain Tumors 2Radiation Oncology Advances Improve Safety and Efficacy of Treatment for Brain Tumors 3
... Signal Genetics, the parent company of Myeloma Health, ... oncology, today announced the formation of their Scientific Advisory ... Director, Jerome Lipper Multiple Myeloma Center, ... Medicine, Harvard Medical School Dr. Anderson of ...
... Calif., Oct. 26 Telik, Inc. (Nasdaq: ... company,s lead therapeutic product candidate, has been selected by ... Top 10 Most Interesting Oncology Projects to Watch."  Windhover ... executives in the pharmaceutical, biotechnology, and medical device industries. ...
... Regado Biosciences, a privately held company leading the development ... David J. Mazzo, PhD, President and CEO, will be ... Mazzo,s presentation will be given at the Waldorf-Astoria Hotel ... at 10:45 a.m. EDT in the Louis XVI Room. ...
Cached Biology Technology:Signal Genetics Announces Establishment of Scientific Advisory Board 2Signal Genetics Announces Establishment of Scientific Advisory Board 3TELINTRA® Named One of the 10 Most Interesting Oncology Projects to Watch 2TELINTRA® Named One of the 10 Most Interesting Oncology Projects to Watch 3Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City 2Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City 3
(Date:6/30/2015)... , June 30, 2015 To bolster its efforts ... HYPR Corp. announced today the addition of two new team ... as board advisor and David Raviv will act ... underscore HYPR Corp.,s commitment to providing the most secure solutions ... Sirota co-founded Layer 7 Technologies, a provider of security ...
(Date:6/25/2015)... , June 25, 2015  Imagine a tool specifically ... a healthier, happier life. That,s exactly what USANA,s ... do. The cutting-edge, portable health program provides a personalized ... to help improve your lifestyle and nutrition. ... and gala Wednesday night, USANA,s THA was honored with ...
(Date:6/24/2015)... 22, 2015 Research ... of the "Huawei Ascend Mate 7 Fingerprint ... their offering. Huawei,s technological choice for ... direction than Apple,s and Samsung,s one. The Ascend ... by Fingerprint Cards, a main actor in capacitive ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... Photosynthesis takes place in specialized membrane systems, made up ... A team of Ludwig-Maximilians-Universitaet (LMU) in Munich has now ... the edge of each stack. Scanning electron microscopy ... mays ) showing thylakoids (green) and assimilation starch granules ...
...  Polymer Technology Systems, Inc. (PTS, Inc.), the U.S.-based manufacturer ... products, has announced the issuance of two new U.S. ... of health data collected by point-of-care testing devices using ... a method and apparatus for manufacturing disposable dry test ...
... 2013 /PRNewswire-iReach/ -- Urologyweb.com, a leading website from Dr. ... outlining which prostate cancers really need treatment. ... favorable-risk Gleason 6 (3+3) prostate cancer and the ... not progress and do not need any treatment whether through ...
Cached Biology News:Photosynthesis: Membranes in tight corners 2PTS, Inc. Announces Two New Patents 2Which Prostate Cancers Really Need Treatment? 2Which Prostate Cancers Really Need Treatment? 3
Sphingosine 1-phosphate receptor Edg-1...
Bag-1 (K-20)...
... atoms at the 3, 3', 4, and ... as an internal standard for the quantification ... LC-mass spectrometry. PGE2 is one of the ... one of the most widely investigated prostaglandins. ...
, Glycerol 30%...
Biology Products: